Table 1 Baseline characteristics stratified by the protocol applied
Characteristics | R-MPL (N=69) | R-MP (N=38) | All (N=107) |
|---|---|---|---|
Median age (range), years | 73 (66–85) | 73 (66–85) | 73 (66–85) |
Female | 34 (49.3) | 16 (42.1) | 50 (46.7) |
Karnofsky performance status a | |||
Median (range) | 70 (30–100) | 60 (30–100) | 70 (30–100) |
⩾70% | 32 (56.1) | 17 (47.2) | 49 (52.7) |
Lymphoma lesions b | |||
Single | 28 (41.2) | 13 (34.2) | 41 (38.7) |
Multiple | 40 (58.8) | 25 (65.8) | 65 (61.3) |
Lymphoma location | |||
Infratentorial | 11 (16.2) | 10 (26.3) | 21 (19.8) |
Supratentorial | 50 (73.5) | 20 (52.6) | 70 (66.0) |
Both | 7 (10.3) | 8 (21.1) | 15 (14.2) |
Serum lactate dehydrogenase c | |||
Elevated | 30 (44.8) | 17 (45.9) | 47 (45.2) |
Normal | 37 (55.2) | 20 (54.1) | 57 (54.8) |
Ocular involvement | 1 (1.5) | 0 (0) | 1 (0.9) |
Histology | |||
DLBCL | 69 (100.0) | 38 (100.0) | 107 (100.0) |
